STATEN ISLAND, N.Y., Nov. 8, 2021 /PRNewswire/ -- Acurx Pharmaceuticals, Inc. (NASDAQ: ACXP) ("Acurx" or the "Company"), a clinical stage biopharmaceutical company developing a new class of ...
Seres Therapeutics reported results from an interim phase 2 trial for its colon infection treatment weren’t found to be statistically significant. 1. The treatment, SER-109, is intended for multiply ...
Acurx Pharmaceuticals (NASDAQ:ACXP) stock plunged 26% in midday trading amid the release of data from a Phase 2b clinical trial for its C. diff treatment ibezapolstat. The biotech company said the ...
Rebiotix, a Ferring Company, and its parent Ferring Pharmaceuticals Group said today their microbiome-based treatment candidate RBX2660 showed positive preliminary Phase III results in patients with ...
A potential Clostridium difficile vaccine performed well in initial tests and now has moved into a large Phase III trial, researchers announced today. The news from developer Sanofi Pasteur raises ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback